Daiichi Sankyo announced today that its subsidiary, ASUBIO PHARMA CO., LTD. (submitted a New Drug Application in Japan for the manufacturing and marketing of SUN Y7017 (generic name: Memantine hydrocholoride), which was developed for the treatment of Alzheimer’s type Dementia (AD).

SUN Y7017 is an N-methyl-D-aspartate (NMDA) receptor antagonist developed by Merz Pharmaceuticals GmbH (Head Office: Germany). This drug was approved for use in the treatment of AD by the European EMEA in 2002 and by the U.S. Food and Drug Administration in 2003. As of January 2010, this drug is marketed in more than 60 countries around the world, and is positioned as a standard care for AD.

continue reading "SUN Y7017, a treatment of Alzheimer’s Type Dementia to approved to launch in Japan"

The Tecan Group and Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the signing of a manufacturing and supply agreement for Enigma’s ML instruments. Under the agreement, Tecan will industrialize and deliver commercially manufactured ML instruments for Enigma’s global market supplies for an initial five-year contract and will also manage the ML instrument’s supply chain. The first ML demonstration instruments have been delivered for Enigma’s GlaxoSmithKline delivery commitments for point-of-care molecular diagnostic influenza tests.

The launch of Enigma ML and supply of commercial series systems for its initial use to identify specific influenza virus strains is anticipated in Q4 2010, subject to successful clinical trials and regulatory approval. Enigma will also add additional tests for other areas such as infectious disease management to the ML system test menu in the future.

continue reading "Tecan and Enigma Diagnostics in agreement for point-of-care Molecular Diagnostics instruments worldwide"